A detailed history of Voya Investment Management LLC transactions in Akero Therapeutics, Inc. stock. As of the latest transaction made, Voya Investment Management LLC holds 22,604 shares of AKRO stock, worth $663,201. This represents 0.0% of its overall portfolio holdings.

Number of Shares
22,604
Previous 19,693 14.78%
Holding current value
$663,201
Previous $497,000 6.64%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$18.31 - $24.62 $53,300 - $71,668
2,911 Added 14.78%
22,604 $530,000
Q1 2024

May 15, 2024

SELL
$17.76 - $31.18 $10,886 - $19,113
-613 Reduced 3.02%
19,693 $497,000
Q4 2023

Feb 14, 2024

SELL
$11.38 - $50.33 $151,410 - $669,640
-13,305 Reduced 39.59%
20,306 $474,000
Q3 2023

Nov 14, 2023

BUY
$41.19 - $52.25 $105,158 - $133,394
2,553 Added 8.22%
33,611 $1.7 Million
Q2 2023

Aug 14, 2023

BUY
$36.89 - $56.88 $171,649 - $264,662
4,653 Added 17.62%
31,058 $1.45 Million
Q1 2023

May 15, 2023

SELL
$37.27 - $50.24 $386,117 - $520,486
-10,360 Reduced 28.18%
26,405 $1.01 Million
Q4 2022

Feb 14, 2023

BUY
$33.44 - $54.8 $863,353 - $1.41 Million
25,818 Added 235.85%
36,765 $2.01 Million
Q3 2022

Mar 03, 2023

SELL
$10.15 - $34.05 $262,052 - $879,102
-25,818 Reduced 70.22%
10,947 $372,000
Q2 2022

Aug 15, 2022

BUY
$8.0 - $15.01 $6,272 - $11,767
784 Added 7.71%
10,947 $103,000
Q4 2021

Feb 14, 2022

BUY
$19.87 - $26.24 $1,907 - $2,519
96 Added 0.95%
10,163 $215,000
Q2 2021

Aug 16, 2021

BUY
$24.81 - $32.35 $249,762 - $325,667
10,067 New
10,067 $250,000

Others Institutions Holding AKRO

About Akero Therapeutics, Inc.


  • Ticker AKRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,417,600
  • Market Cap $1.36B
  • Description
  • Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...
More about AKRO
Track This Portfolio

Track Voya Investment Management LLC Portfolio

Follow Voya Investment Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Voya Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Voya Investment Management LLC with notifications on news.